Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

NCT01208662

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arizona Comprehensive Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California at San Diego La Jolla, California, United States
View all 46 locations
View Trial Details
Active, Not Recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General/North Shore Cancer Center Danvers, Massachusetts, United States
  • Newton-Wellesley Hospital Newton, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +18 more
Locations
  • California Research Institute Los Angeles, California, United States
  • Innovative Clinical Research Institute Whittier, California, United States
  • Oncology-Hematology Associates of West Broward Coral Springs, Florida, United States
  • New Jersey Center for Cancer Research Brick, New Jersey, United States
View all 108 locations
View Trial Details
Active, Not Recruiting

Communication Skills Intervention to Promote Transition Into Survivorship

NCT01483664

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations
  • Tampa General Hospital Tampa, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Memorial Sloan Kettering at Basking Ridge Basking Ridge, New Jersey, United States
  • Maimonides Medical Center Brooklyn, New York, United States
View Trial Details
Active, Not Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham, Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

NCT05737628

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo, Italy
  • Instituto Europeo di Oncologia Milan, Italy
  • IRCCS Ospedale San Raffaele Milan, Italy
View Trial Details
Active, Not Recruiting

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Morristown Memorial Hospital Morristown, New Jersey, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR Dallas, Texas, United States
  • Vista Oncology Olympia, Washington, United States
  • UK St. Pölten Sankt Pölten, Lower Austria, Austria
View all 62 locations
View Trial Details
Active, Not Recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Créteil Hopital Henri Mondor Créteil, France
  • Dijon CHU Hopital le Bocage Dijon, France
  • Clermont Ferrand CHU Estaing Estaing, France
  • Grenoble CHU Pontchaillou Grenoble, France
View all 38 locations
View Trial Details
Active, Not Recruiting

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

NCT05716087

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Anhui provincial cancer hospital Hefei, Anhui, China
  • The first affiliated hospital of Anhui medical university Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
View all 43 locations
View Trial Details

Related conditions